92 results on '"Forconi, Francesco"'
Search Results
2. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
3. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
4. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
5. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
6. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
7. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL
8. IL-4 enhances expression and function of surface IgM in CLL cells
9. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation
10. Perturbation of the normal immune system in patients with CLL
11. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
12. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
13. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK
14. CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
15. Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
16. Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
17. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
18. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function
19. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis
20. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
21. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
22. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
23. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma
24. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
25. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia
26. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia
27. The normal IGHV1-69–derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL
28. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior
29. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
30. DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1
31. EMT-like Activation in CLL Provides Novel Therapeutic Target
32. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch
33. Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance
34. Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia
35. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
36. International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia
37. Immunoglobulin Variable Region Gene Sequences Reveal N-Glycosylation Motifs As an Early and Stable Event in Follicular Lymphoma Pathology
38. Lymphoma-Specific Subversion of B-Cell Receptor Signaling By Macrophage Lectins
39. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia
40. Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM)
41. The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells
42. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation
43. Regulation and Impact of BCR Induced Autophagy in Chronic Lymphocytic Leukemia
44. Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy
45. BRAF and BIRC3 Mutations Stratify a Poor Prognostic Subgroup in FCR Treated Chronic Lymphocytic Leukemia
46. Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL
47. Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment
48. Early Enhancement of IgM Expression and Signaling Capacity during Ibrutinib Therapy in CLL Patients
49. PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis
50. Biological Significance of B Cell Receptor Mediated Regulation of Autophagy in Chronic Lymphocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.